StockNews.AI
SAGE
StockNews.AI
203 days

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

1. Sage Therapeutics will report Q4 2024 financial results on February 11. 2. A live webcast will discuss financial performance and business updates. 3. Sage is a leader in brain health medicine with FDA-approved treatments.

7m saved
Insight
Article

FAQ

Why Neutral?

Financial reports typically have mixed impacts. Past results have shown volatility in response.

How important is it?

Earnings report could shift perceptions but not guarantee substantial movement.

Why Short Term?

Upcoming financial results could influence investor sentiment. Immediate market reactions are expected.

Related Companies

SAGEVRTXZMAMGN

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

CAMBRIDGE, Mass.--( )--Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial results and discuss recent business updates.

The webcast can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.

About Sage Therapeutics

Sage Therapeutics (Nasdaq: SAGE) is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com or engage with us on Facebook, LinkedIn, Instagram, and X.

Contacts

Investor Contact
Ashley Kaplowitz
Ashley.Kaplowitz@sagerx.com

Media Contact
Francesca Dellelci
Francesca.Dellelci@sagerx.com

Related News